全文获取类型
收费全文 | 1902篇 |
免费 | 117篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 75篇 |
妇产科学 | 29篇 |
基础医学 | 196篇 |
口腔科学 | 64篇 |
临床医学 | 229篇 |
内科学 | 336篇 |
皮肤病学 | 42篇 |
神经病学 | 100篇 |
特种医学 | 277篇 |
外科学 | 194篇 |
综合类 | 43篇 |
预防医学 | 197篇 |
眼科学 | 16篇 |
药学 | 152篇 |
肿瘤学 | 93篇 |
出版年
2023年 | 6篇 |
2022年 | 4篇 |
2021年 | 33篇 |
2020年 | 9篇 |
2019年 | 23篇 |
2018年 | 33篇 |
2017年 | 17篇 |
2016年 | 22篇 |
2015年 | 31篇 |
2014年 | 47篇 |
2013年 | 54篇 |
2012年 | 60篇 |
2011年 | 75篇 |
2010年 | 55篇 |
2009年 | 41篇 |
2008年 | 60篇 |
2007年 | 86篇 |
2006年 | 81篇 |
2005年 | 61篇 |
2004年 | 63篇 |
2003年 | 65篇 |
2002年 | 50篇 |
2001年 | 45篇 |
2000年 | 51篇 |
1999年 | 51篇 |
1998年 | 69篇 |
1997年 | 78篇 |
1996年 | 89篇 |
1995年 | 59篇 |
1994年 | 47篇 |
1993年 | 46篇 |
1992年 | 40篇 |
1991年 | 34篇 |
1990年 | 46篇 |
1989年 | 55篇 |
1988年 | 57篇 |
1987年 | 42篇 |
1986年 | 40篇 |
1985年 | 43篇 |
1984年 | 21篇 |
1983年 | 16篇 |
1982年 | 19篇 |
1981年 | 16篇 |
1980年 | 14篇 |
1979年 | 14篇 |
1978年 | 10篇 |
1977年 | 16篇 |
1976年 | 12篇 |
1975年 | 13篇 |
1972年 | 6篇 |
排序方式: 共有2048条查询结果,搜索用时 15 毫秒
1.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome. 相似文献
2.
Gregory Guldner MD MS Jason Schultz BS Perry Sexton MD Corwyn Fortner BS Mark Richmond MD 《Academic emergency medicine》2003,10(2):134-139
OBJECTIVES: Physicians commonly use etomidate for adult rapid-sequence intubation (RSI), but the manufacturer does not recommend its use for children under 10 years of age due to a lack of data. The authors present their experience with etomidate for pediatric RSI in order to further develop its risk-benefit profile in this age group. METHODS: Trained abstractors reviewed the medical records for all children under 10 years old who received etomidate for RSI between July 1996 and April 2001. RESULTS: 105 children, with an average age of 3 (+/-2.9) years, received a median dose of 0.32 (+/-0.12) mg/kg of etomidate. The systolic blood pressure increased an average of 4 mm Hg (95% CI = -3.3 to 9.2); the diastolic blood pressure increased 7 mm Hg (95% CI = -3.1 to 11) within 10 minutes of receiving etomidate. The heart rate increased an average of 10 beats/min (95% CI = 4.0 to 17.4). Complications included three patients who vomited within 10 minutes of etomidate administration. There were no cases of documented myoclonus, status epilepticus, or new-onset seizures. Thirty-eight patients received corticosteroids during the hospital course, none for suspected adrenal insufficiency. Three patients died, all from severe brain injury. CONCLUSIONS: In children less than 10 years old, etomidate seems to produce minimal hemodynamic changes, and appears to have a low risk of clinically important adrenal insufficiency, myoclonus, and status epilepticus. The association between etomidate and emesis (observed in less than 3% of enrolled patients) remains unclear. For clinical situations in which minimal blood pressure changes during RSI are critical, etomidate appears to have a favorable risk-benefit profile for children under 10 years old. 相似文献
3.
4.
Sonoelasticity imaging of prostate cancer: in vitro results 总被引:2,自引:0,他引:2
5.
6.
7.
8.
9.
10.
Ten thrombocytopenic patients (platelets < 10–24 × 10(9)/L) who were refractory to platelet transfusion were investigated for their responsiveness to staphylococcal protein A column therapy. Nine patients had previously been treated with steroids, intravenous immune globulin, and/or other forms of immunosuppressive therapy without improvement in their transfusion response. All patients were receiving multiple platelet transfusions without achieving 1-hour corrected count increments (CCIs) > or = 7500. Eight patients had antibodies that reacted with platelets and were directed against HLA class I antigens, ABO antigens, and/or platelet-specific alloantigens. Plasma (500-2000 mL) from each patient was passed over a protein A silica gel column and then returned to the patient. Patients received from 1 to 14 treatments. A positive response to protein A therapy was defined as at least a doubling of the pretreatment platelet count and/or two successive 10- to 120-minute posttransfusion CCIs > or = 7500. Following plasma treatments, 6 of 10 patients responded with daily platelet counts that averaged 48 +/− 11 × 10(9) per L as compared with counts of 16 +/− 7 × 10(9) per L (p < 0.0005) before treatment. Posttransfusion CCI values determined in four of these patients averaged 2480 +/− 810 and 10,010 +/− 3540 (p < 0.005) before and after treatment, respectively. In contrast, among the four unresponsive patients, platelet counts averaged 10 +/− 9 and 13 +/− 10 × 10(9) per L (p = NS), respectively, while posttransfusion CCIs were 700 +/− 1410 and 1520 +/− 2460 (p = NS), respectively.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献